NFG
CRSP icon

Next Financial Group’s CRISPR Therapeutics CRSP Stock Holding History

Next Financial Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$269K Buy
3,558
+299
+9% +$26.1K 0.02% 779
2021
Q3 		$365K Buy
3,259
+43
+1% +$5.4K 0.03% 597
2021
Q2 		$520K Sell
3,216
-174
-5% -$21.2K 0.04% 446
2021
Q1 		$413K Buy
3,390
+1,116
+49% +$169K 0.04% 495
2020
Q4 		$349K Buy
2,274
+571
+34% +$67.5K 0.03% 502
2020
Q3 		$143K Buy
+1,703
New +$151K 0.02% 732
2020
Q2 		– Sell
-883
Closed -$37K – 853
2020
Q1 		$37K Buy
883
+758
+606% +$39.1K ﹤0.01% 1080
2019
Q4 		$8K Sell
125
-484
-79% -$26.4K ﹤0.01% 1834
2019
Q3 		$25K Buy
609
+549
+915% +$26.2K ﹤0.01% 1347
2019
Q2 		$3K Buy
+60
New +$2.4K ﹤0.01% 1995
2019
Q1 		– Sell
-130
Closed -$4K – 1696
2018
Q4 		$4K Buy
+130
New +$4.52K ﹤0.01% 1587

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Next Financial Group's CRSP Position: Q4 2021 in Review

Next Financial Group increased its CRISPR Therapeutics (CRSP) stake by 9.2% in Q4 2021, buying an estimated $26.1K and bringing the position to 3,558 shares worth $269K. The position accounts for 0.02% of the portfolio, ranked #779.

Next Financial Group first reported a position in CRSP in Q4 2018 and has held it in 11 quarters since. The position peaked at $520K in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Next Financial Group held 3,558 shares of CRISPR Therapeutics worth $269K as of Q4 2021.
  • Next Financial Group bought 299 CRISPR Therapeutics shares in Q4 2021, an estimated $26.1K.
  • CRISPR Therapeutics made up 0.02% of Next Financial Group's portfolio in Q4 2021, its #779 holding.
  • Next Financial Group first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 11 quarters since.
  • Next Financial Group's CRISPR Therapeutics position peaked at $520K in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Next Financial Group's 13F filing for Q4 2021, filed 15 Feb 2022.